C12N 2750/14345
Special targeting system for viral vectors
C12N2750/14345 (Special targeting system for viral vectors) appears on 4 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 8
- Assignees
- 5
- Inventors
- 16
- Latest grant
- 4 Feb 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 2 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
By publication year.
Recent patents
- Viral vectors for the treatment of retinal dystrophy4 Feb 2020US 10,550,404 B2Novartis AG
- Viral vectors for the treatment of retinal dystrophy31 Oct 2017US 9,803,217 B2Novartis AG
- Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof21 Mar 2017US 9,598,468 B2University of Florida Research Foundation, Inc.
- Viral vectors for the treatment of retinal dystrophy20 Oct 2015US 9,163,259 B2Novartis AG
- Viral vectors for the treatment of retinal dystrophy12 Oct 2023US 2023/0323398 A1Novartis AG
- Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy7 Sep 2023US 2023/0277687 A1Consorcio Centro De InvestigacióN BioméDica En Red Del áRea De Enfermedades Neurodegenerativas M.P C
- Viral vectors for the treatment of retinal dystrophy18 Feb 2021US 2021/0047656 A1Novartis AG
- Cationic nanoparticles for enhancing infectious capacity of live viruses27 Feb 2020US 2020/0060981 A1
- Viral vectors for the treatment of retinal dystrophy22 Mar 2018US 2018/0080046 A1Novartis AG
Most cited
By later US patents
- Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof40US 9,598,468 B2University of Florida Research Foundation, Inc. · 2017
- Viral vectors for the treatment of retinal dystrophy13US 9,163,259 B2Novartis AG · 2015
- Viral vectors for the treatment of retinal dystrophy1US 9,803,217 B2Novartis AG · 2017